Evidence map›Paper›PMID 37636024›Full record

ReviewEXCLI journal2023

CRISPR/Cas9 genome editing for neurodegenerative diseases.

Jafar Nouri Nojadeh, Nur Seren Bildiren Eryilmaz, Berrin Imge Ergüder

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EXCLI journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jafar Nouri NojadehAnkara University Faculty of Medicine, Department of Medical Biochemistry, Ankara, Turkey.
Nur Seren Bildiren EryilmazAnkara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
Berrin Imge ErgüderAnkara University Faculty of Medicine, Department of Medical Biochemistry, Ankara, Turkey.
Ankara University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy has emerged as a promising therapeutic strategy for various conditions, including blood disorders, ocular disease, cancer, and nervous system disorders. The advent of gene editing techniques has facilitated the ability of researchers to specifically target and modify the eukaryotic cell genome, making it a valuable tool for gene therapy. This can be performed through either

Indexed as

Alzheimer's diseaseAmyotrophic lateral sclerosisCRISPR/Cas9gene editingHuntington's diseaseneurodegenerative disordersParkinson's diseaseSpinocerebellar ataxia

Identifiers

PMID37636024
PMCPMC10450213
OpenAlexW4386209643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.